Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
LXRX Lexicon Pharmaceuticals Inc
- Stocks
- Healthcare
- NASDAQ: LXRX
Price (delayed)
$0.63
Market cap
$227.74M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.63
Enterprise value
$261.38M
Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients' lives. Through its Genome5000™ program, Lexicon scientists studied the role and function of nearly 5,000 genes
Highlights
The company's EPS rose by 21% YoY and by 16% QoQ
Lexicon Pharmaceuticals's gross margin has increased by 5% YoY and by 4.8% from the previous quarter
Lexicon Pharmaceuticals's equity has surged by 57% YoY but it has decreased by 18% QoQ
The net income has decreased by 13% YoY but it has increased by 7% from the previous quarter
Lexicon Pharmaceuticals's quick ratio has decreased by 26% from the previous quarter
Key stats
What are the main financial stats of LXRX
Market
Valuations
Earnings
Shares outstanding
361.49M
Market cap
$227.74M
Enterprise value
$261.38M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.56
Price to sales (P/S)
6.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.41
Revenue
$31.08M
Gross profit
$30.47M
Operating income
-$197.12M
Net income
-$200.4M
EBIT
-$184.82M
EBITDA
-$184.29M
Free cash flow
-$179.81M
Per share
Balance sheet
Liquidity
EPS
-$0.63
EPS diluted
-$0.63
Free cash flow per share
-$0.56
Book value per share
$0.4
Revenue per share
$0.1
TBVPS
$0.79
Total assets
$298.42M
Total liabilities
$152.47M
Debt
$100.3M
Equity
$145.95M
Working capital
$200.95M
Debt to equity
0.69
Current ratio
5.44
Quick ratio
5.34
Net debt/EBITDA
-0.18
Margins
Efficiency
Dividend
EBITDA margin
-592.9%
Gross margin
98%
Net margin
-644.8%
Operating margin
-634.2%
Return on assets
-56.8%
Return on equity
-93.9%
Return on invested capital
-58.2%
Return on capital employed
-73%
Return on sales
-594.7%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
LXRX stock price
How has the Lexicon Pharmaceuticals stock price performed over time
Intraday
-6.51%
1 week
-3.95%
1 month
23.09%
1 year
-66.31%
YTD
-14.69%
QTD
36.72%
Financial performance
How have Lexicon Pharmaceuticals's revenue and profit performed over time
Revenue
$31.08M
Gross profit
$30.47M
Operating income
-$197.12M
Net income
-$200.4M
Gross margin
98%
Net margin
-644.8%
LXRX's operating margin has surged by 96% year-on-year and by 84% since the previous quarter
LXRX's net margin has surged by 96% year-on-year and by 84% since the previous quarter
The operating income has declined by 15% year-on-year but it has grown by 7% since the previous quarter
The net income has decreased by 13% YoY but it has increased by 7% from the previous quarter
Price vs fundamentals
How does LXRX's price correlate with its fundamentals
Growth
What is Lexicon Pharmaceuticals's growth rate over time
Valuation
What is Lexicon Pharmaceuticals stock price valuation
P/E
N/A
P/B
1.56
P/S
6.49
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
8.41
The company's EPS rose by 21% YoY and by 16% QoQ
Lexicon Pharmaceuticals's equity has surged by 57% YoY but it has decreased by 18% QoQ
The P/B is 54% lower than the 5-year quarterly average of 3.4 and 29% lower than the last 4 quarters average of 2.2
LXRX's price to sales (P/S) is 99% less than its 5-year quarterly average of 991.5 and 95% less than its last 4 quarters average of 128.6
Efficiency
How efficient is Lexicon Pharmaceuticals business performance
The company's return on sales has surged by 96% YoY and by 84% QoQ
The company's return on equity rose by 33% YoY and by 13% QoQ
LXRX's ROA is up by 21% YoY and by 12% QoQ
LXRX's ROIC is up by 21% YoY and by 8% from the previous quarter
Dividends
What is LXRX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for LXRX.
Financial health
How did Lexicon Pharmaceuticals financials performed over time
The total assets is 96% greater than the total liabilities
The total assets has grown by 30% year-on-year but it has declined by 7% since the previous quarter
The current ratio has contracted by 27% from the previous quarter and by 2.9% YoY
LXRX's debt is 31% smaller than its equity
Lexicon Pharmaceuticals's equity has surged by 57% YoY but it has decreased by 18% QoQ
Lexicon Pharmaceuticals's debt to equity has decreased by 36% YoY but it has increased by 23% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.